SCHEMBL22060174

SCHEMBL22060174

Cc1ccccc1C(=O)Nc1nc(NC(=O)c2cccnc2)nn1-c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.55
LMNA P02545 4/20 0.49
CDKN1A P38936 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.48
HTT P42858 5/20 0.48
POLB P06746 2/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HIF1A Q16665 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
ALOX15 P16050 1/20 0.46
ATM Q13315 1/20 0.45
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CYP11B2 P19099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22060703 0.92 MAPK1 (0.65) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL22060705 0.90 MAPK1 (0.57) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL22060710 0.90 MAPK1 (0.63) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL20110246 0.90 MAPK1 (0.56) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL22060729 0.88 MAPK1 (0.54) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL20110228 0.86 MAPK1 (0.54) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL22060323 0.86 CDKN1A (0.52) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL22060170 0.84 KMT2A (0.56) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL20110191 0.83 MAPK1 (0.79) MAPK1LMNACDKN1ASMN1; SMN2HTT
SCHEMBL20110192 0.83 MAPK1 (0.79) MAPK1LMNACDKN1ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210244712-A1 METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION NYSNOBIO IRELAND DAC (IE) 2021-08-12 US disclosed
US-20210230126-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2021-07-29 US disclosed
US-10889553-B2 Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same NYSNOBIO IRELAND DAC (IE) 2021-01-12 US disclosed
US-20200172497-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2020-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210244712-A1 METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION TP53, RB1, CDK1 MAPK1 723/4885LMNA 1905/4885CDKN1A 7/4885
US-20200172497-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME ATG7, PINK1, ADRM1 MAPK1 2259/4885LMNA 1956/4885CDKN1A 594/4885
US-20210230126-A1 ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME ATG7, PINK1, ADRM1 MAPK1 2259/4885LMNA 1956/4885CDKN1A 594/4885
US-10889553-B2 Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same ATG7, PINK1, ADRM1 MAPK1 2259/4885LMNA 1956/4885CDKN1A 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.